Rate of local tumor progression following radiofrequency ablation of pathologically early hepatocellular carcinoma

Yoshiteru Hao(Yokohama City University Medical Center), Katsuaki Tanaka(Yokohama City University Medical Center), Shin Maeda(University of Tokyo Hospital), Hiroyuki Fukuda(Yokohama City University Medical Center), Masayuki Nakano(Nihon University), Tomohiro Ishii(Tokyo Metropolitan Children's Medical Center), Kazushi Numata(Yokohama City University Medical Center)
World Journal of Gastroenterology
January 1, 2017
10.3748/wjg.v23.i17.3111
Cited by 29

Related Papers

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
|European Journal of Cancer|2011|573
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Imaging Study of Early Hepatocellular Carcinoma: Usefulness of Gadoxetic Acid–enhanced MR Imaging
|Radiology|2011|354
cHCC‐CCA
|Hepatology|2018|333